Morinda citrifolia, commonly known as noni, is a traditional natural medicine in French Polynesia and Hawaii. Functional foods derived from M. citrifolia fruit have been marketed to help prevent diseases and promote good health. The objective of this study was to assess the effects of M. citrifolia fruit on cellmediated immunity. In the picryl chloride-induced contact dermatitis test, M. citrifolia fruit extract (Noni-ext) inhibited the suppression of cell-mediated immunity by immunosuppressive substances isolated from freeze-dried ascites of Ehrlich carcinoma-bearing mice (EC-sup). In addition, Noni-ext inhibited reduction of IL-2 production in EC-sup-treated mice and activated natural killer cells in normal mice. These results suggest that Noni-ext has multiple effects on the recovery of cell-mediated immunity. Furthermore, we investigated the active principles of Noni-ext and identified an iridoid glycoside, deacetylasperulosidic acid. Oral administration of deacetylasperulosidic acid inhibited the reduction of ear swelling, and also cancelled the suppression of IL-2 production along with the activation of natural killer cells in the same manner as that of Noni-ext.
Fermented noni fruit juice is consumed as a dietary supplement for preventive purposes rather than as a treatment. We hypothesized that the immunomodulating property of noni fruit is a main contributor to its disease preventing properties.
The immune system defends against foreign bodies such as microbes and viruses, thereby playing an important role in sustaining life. Immune dysfunction is one of the causes of infections and metabolic syndrome including diabetes and cancer. Immune reactions involve the following steps: Antigens stimulate naive helper T-cells (Th0) to differentiate into either Type 1 helper T cells (Th1) or Type 2 helper T cells (Th2) [6] . Th1 cells release cytokines, interferon (IFN)-gamma and interleukin (IL)-2, and activate cytotoxic T lymphocytes and natural killer (NK) cells. Thus, cell-mediated immunity is activated. Th2 cells release IL-4 and IL-10 to activate B cells and humoral immunity [6] [7] .
Because cell-mediated immunity provides resistance against infections and cancer through T cells, we investigated the effect of noni fruit on cell-mediated immunity. Nayak et al. [8] previously reported that noni fruit enhanced the cell-mediated immunity. In the footpad reaction of the delayed-type hypersensitivity (DTH) model, noni restored the cell-mediated immunity of mice which was immunosuppressed by prednisolone, a type of steroid hormone. We further used immunosuppressive substances isolated from freezedried ascites of Ehrlich carcinoma-bearing mice (EC-sup). Cellmediated immunity is frequently dormant in cancer patients and tumor bearing animals, and immunosuppressive substances secreted from carcinoma cells have been known to disrupt immune cells [9] . Furthermore, EC-sup has been reported to suppress swelling in the footpad reaction model, demonstrating suppression of cell-mediated immunity [10] . The EC-sup animal model may be suitable for investigating the preventive effects of noni extracts.
This study aimed to determine if noni-ext modulates cell-mediated immunity in EC-sup immunosuppressed mice using the picryl chloride-induced contact dermatitis (PC-CD) test (DTH model). In addition, it was designed to evaluate the ability of noni fruit extract to modify production of cytokines and NK cytotoxic activity against Yac-1 lymphoma cells. 
Effect of noni-ext on cytokine production in splenocytes:
Because Noni-ext reactivated suppressed cell-mediated immunity, the production of IL-2, IL-4, and IL-10 was measured to understand the mechanism. IL-2 production of EC-sup-treated (vehicle control) mice was significantly lower than that of EC-sup-untreated (control) mice (Figure 2 B-a). This suggests that EC-sup inhibited the cell-mediated immune response. In contrast, the amount of IL-4 and IL-10 was not changed (Figure 2 B-b, c). When noni-ext was administered orally at 1000 mg/kg for 2 weeks before EC-sup treatment, significant decrease of IL-2 production was observed compared with vehicle control (Figure 2 B-a). In contrast, IL-2 production tended to increase in normal mice when noni-ext was administered, as observed in Figure 2 A. IL-4 and IL-10 decreased slightly, but the difference was not significant, when compared with the control group (Figure 2 A) . None of the mice in these groups showed weight loss. 
NK cytotoxic activity of noni-ext against Yac-1 lymphoma cells:
The NK cytotoxic activity of noni-ext was determined by measuring its cytotoxicity against NK-sensitive Yac-1 lymphoma cells. While NK cytotoxic activity was 2% in the control group, the noni-ext treated (1000 mg/kg) group significantly increased to 12% ( Figure  3 ). None of the groups showed any weight loss. 
Effect of noni-ext on lymphocyte subpopulations in splenocytes:
Lymphocytes including T cells are important in the immune system. Therefore, we evaluated how noni-ext affected lymphocyte subpopulations (CD3 + , CD4 + , CD8 + , CD45R/B220 + , and CD49b + cells) using flow cytometry. No changes in the T and B lymphocyte subpopulations were observed for noni-ext (Table 1 ). In addition, these were not affected by EC-sup administration ( Table 1) . None of the groups showed any weight loss. Each value represents the mean ± S.E. of 3-4 mice.
Effect of deacetylasperulosidic acid (1) on the cell-mediated immune response:
Noni-ext reversed the weakened cell-mediated immune response. Active compounds in three separate fractions [ethyl acetate (EtOAc), n-butanol (BuOH), and water] were screened in the PC-CD test. Figure 4 illustrates that the BuOH-and water-soluble fractions inhibited the reduction of the cell-mediated immune response, in a dose-dependent manner at 50 and 200 mg/kg. We identified and quantified 1 in BuOH (30.1 mg/g) and water-soluble fractions (18.3 mg/g) using HPLC. Since compound 1 was a main component from TLC and HPLC analysis, the PC-CD test was performed to examine the immune-stimulating activity of 1. Oral administration of 1 at either 30 or 100 mg/kg inhibited the reduction of ear swelling by 55 and 52%, respectively ( Figure 5 ). This demonstrates that at least a portion of the immune-stimulating activity in noni-ext resulted from the activity of 1. 
Effect of 1 on cytokine production, NK cytotoxic activity and lymphocyte subpopulations:
We then investigated how 1 mediates cytokine production, NK cytotoxicity, and lymphocyte subpopulations. We observed that 1 administered orally at a dose of 100 mg/kg inhibited reduction of IL-2 production in EC-sup-treated mice (Figure 6 B-a). While the control group showed an average of 2% NK cytotoxicity, the groups treated with 1 at 30 or 100 mg/kg had significantly higher cytotoxicity, i.e., 12 and 21%, respectively ( Figure 7 ). Normal mice that were fed 1 did not show a statistically significant change, although there was an increasing trend in IL-2 production and a decreasing trend in IL-4 and IL-10 production (Figure 6 A) . Compound 1 had no effect on lymphocyte subpopulations ( Table 2 ). The immune system plays an important role in human health [11] [12] [13] . Safe, and natural immunostimulants are therefore of great value and are being sought by several researchers [11] . We were interested in noni, which is a traditional food as well as a folk medicine and hypothesized that the active principle should improve immunity.
We demonstrated that noni-ext restored cell-mediated immunity suppressed by EC-sup. In addition, we showed that reduction of IL-2 production was restored and that NK cells were activated. These results suggest that noni-ext has multiple functions in the recovery of cell-mediated immunity.
Noni-ext showed a weaker response in MTX-treated mice than in EC-sup-treated mice because each of these suppresses immunity by a different mechanism. EC-sup hampers cell-mediated immunity by disrupting the interaction between macrophages and T cells and the number of lymphocytes remains unchanged [14] . In contrast, MTX inhibits the proliferation of lymphocytes. The different responses to Noni-ext indicate that it had no effect on subpopulations and proliferation of immune cells.
Over-reaction of cell-mediated immunity and/or Th1 leads to autoimmunity [15] . Noni-ext did not significantly affect IL-2 expression in normal mice. This suggests that noni-ext may not exaggerate the immune response or cause side effects of autoimmunity. In addition, noni-ext did not change either IL-4 or IL-10 production. The target of noni-ext was limited to cellmediated immunity and it should not provoke either allergic or inflammatory reactions. We have presented scientific evidence that noni-ext can reactivate disabled cell-mediated immunity without serious side effects.
In addition, we identified 1, a constituent of noni fruit, as a potent immunostimulant. Although it has been known to inhibit lowdensity lipoprotein oxidation [16] and melanin production [17] in vitro, this is the first time that it has been shown to reactivate impaired cell-mediated immunity in vivo. In addition, this is the first report to identify a specific compound in noni fruit as an immunostimulant.
It is widely known that polysaccharides stimulate the immune system [18] [19] [20] . Lipopolysaccharides (LPS), in particular, aggressively stimulate immunity and release cytokine nonspecifically. Therefore, the polysaccharides in noni-ext cannot be excluded as active compounds [21] . However, noni-ext showed outcomes different from those of LPS. In addition, 1 shared similar bioactivities with noni-ext and appeared to be an important compound, as evidenced by its effectiveness and its concentration in noni-ext. These results suggest that 1 would be a useful tool in immunological research in future.
In our experiments, noni-ext was used at a very high dose, i.e., 200 to 1000 mg/kg. However, this would be equivalent to only 1 to 5 g/day of noni-ext or 2 to 10 g/day of dried noni fruit powder in a human trial. These amounts are reasonable for daily human consumption. Therefore, we recommend the use of noni fruit as a promising natural herb to prevent various diseases. In future studies, we will further investigate additional mechanisms and discover the effectiveness of noni fruit. 
Preparation of dried supernatant of ascites from Ehrlich carcinoma bearing-mice (EC-sup):
EC-sup was prepared according to the method of Yamazaki et al. [23] , with minor modifications. Ascites was collected from the female ICR strain mice which had been intraperitoneally injected with 5 × 10 6 Ehrlich carcinoma cells in saline 8−12 days earlier. After centrifuging the ascites for 10 min at 1000 × g at 5°C to remove cells, the supernatant was freeze-dried to produce Ehrlich carcinomasupernatant (EC-sup).
Picryl chloride-induced contact dermatitis (PC-CD) test in
immunocompromised mice: Following the method described by Asherson and Ptak [24] , with minor modification, female ICR strain mice were sensitized by topical application of 0.1 mL of 7% picryl chloride (PC) solution in ethanol to the shaved abdomen (day 1). After sensitization, a test sample and the reference drug Krestin were suspended in 0.2% carboxymethylcellulose sodium (CMC-Na) solution and orally administered (0.2 mL/10 g body weight/day) from day 1 to day 7. The control group was treated with 0.2% CMC-Na solution (p.o., for 7 days). Six days after sensitization (day 7), the mice received injections of EC-sup (i.p., 1000 mg/kg in saline; 0.9%, w/v, NaCl) or MTX (i.p., 200 mg/kg in saline). The next day (day 8), mice were challenged by painting the inside of their ears with 0.02 mL of 1% PC solution in olive oil to induce PC-CD. Ear swelling was expressed as the difference in ear thickness, measured using calipers, between immediately before and 24 h after the PC challenge. The experimental results are expressed as the average increase in ear thickness ± S.E. The rate of increase in ear thickness was calculated using the following formula: Inhibition of reduced ear edema (%) = [(control group − vehicle control group) − (control group − sample group)]/(control group − vehicle control group) × 100. Body weight of the animals was measured every 2 days, and body weight changes were confirmed. After the final measurement of ear thickness (24 h after PC challenge), the mice were sacrificed by dislocation of the cervical vertebrae, and their organs (adrenal gland, thymus, and spleen) were dissected. The weights of the organs were measured and expressed as a ratio of organ weight per 10 g body weight.
Treatment of animals and experimental design:
Female BALB/c mice were divided into 6 treatment groups (C, N-200, N-500, N-1000, D-30, and D-100) to evaluate the effects of samples in normal mice. The C group constituted the control, treated with 0.2% CMC-Na solution (p.o., for 14 days). The N groups were treated with noni-ext (200, 500, and 1000 mg/kg/day) suspended in 0.2% CMC-Na solution (p.o., for 14 days). The D groups were treated with compound 1 (30 and 100 mg/kg/day) suspended in 0.2% CMC-Na solution (p.o., for 14 days). To evaluate the effects of samples in EC-sup-treated mice, female BALB/c mice were divided into 7 groups (C, VC, N-200, N-500, N-1000, D-30, and D-100). The VC group constituted the vehicle control, treated with 0.2% CMC-Na solution (p.o., for 14 days). Other groups were treated as described above. At days 13 and 14, all groups apart from C were administered EC-sup (i.p., 1,000 mg/kg in saline) to impair immune function. On the day before the final day of treatment (day 15), spleens were dissected from the mice for further experiments. Their body weights were measured every 2 days, and body weight changes were confirmed.
